Abbott Laboratories $ABT Stock Holdings Boosted by Focus Partners Advisor Solutions LLC

Key Points

• Focus Partners Advisor Solutions LLC increased its holdings in Abbott Laboratories by 13.2%, now owning 21,732 shares valued at approximately $2.95 million.
• Abbott Laboratories reported a quarterly earnings per share of $1.30, meeting analysts' estimates, with a revenue of $11.37 billion.
• The company recently declared a quarterly dividend of $0.59, with an annualized yield of 1.9% and a payout ratio of 29.57%.

Focus Partners Advisor Solutions LLC raised its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 13.2% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 21,732 shares of the healthcare product maker's stock after purchasing an additional 2,531 shares during the quarter. Focus Partners Advisor Solutions LLC's holdings in Abbott Laboratories were worth $2,954,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Curio Wealth LLC lifted its position in shares of Abbott Laboratories by 15,250.0% during the 2nd quarter. Curio Wealth LLC now owns 307 shares of the healthcare product maker's stock valued at $42,000 after acquiring an additional 305 shares during the last quarter. Richards Merrill & Peterson Inc. lifted its position in shares of Abbott Laboratories by 11.6% during the 2nd quarter. Richards Merrill & Peterson Inc. now owns 7,712 shares of the healthcare product maker's stock valued at $1,049,000 after acquiring an additional 804 shares during the last quarter. PKO Investment Management Joint Stock Co lifted its position in shares of Abbott Laboratories by 105.9% during the 2nd quarter. PKO Investment Management Joint Stock Co now owns 37,060 shares of the healthcare product maker's stock valued at $5,041,000 after acquiring an additional 19,060 shares during the last quarter. Pinnacle Wealth Management Group Inc. acquired a new stake in shares of Abbott Laboratories during the 2nd quarter valued at $303,000. Finally, Sage Mountain Advisors LLC lifted its position in shares of Abbott Laboratories by 7.2% during the 2nd quarter. Sage Mountain Advisors LLC now owns 16,334 shares of the healthcare product maker's stock valued at $2,222,000 after acquiring an additional 1,102 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company's stock.

Abbott Laboratories Trading Up 0.3%

NYSE ABT opened at $126.78 on Friday. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $220.65 billion, a PE ratio of 15.89, a price-to-earnings-growth ratio of 2.41 and a beta of 0.69. The firm's fifty day simple moving average is $132.09 and its 200-day simple moving average is $131.61.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, hitting analysts' consensus estimates of $1.30. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.78%. The business had revenue of $11.37 billion for the quarter, compared to the consensus estimate of $11.40 billion. During the same period in the prior year, the business posted $1.21 earnings per share. Abbott Laboratories's revenue for the quarter was up 6.9% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, sell-side analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be paid a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.9%. Abbott Laboratories's dividend payout ratio is 29.57%.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Daiwa Capital Markets increased their price objective on Abbott Laboratories from $134.00 to $136.00 and gave the company an "outperform" rating in a research report on Tuesday, October 21st. Jefferies Financial Group increased their target price on Abbott Laboratories from $145.00 to $149.00 and gave the company a "buy" rating in a report on Thursday, October 16th. The Goldman Sachs Group increased their target price on Abbott Laboratories from $153.00 to $157.00 and gave the company a "buy" rating in a report on Wednesday, October 1st. Mizuho increased their target price on Abbott Laboratories from $135.00 to $140.00 and gave the company a "neutral" rating in a report on Tuesday, October 14th. Finally, Wells Fargo & Company increased their target price on Abbott Laboratories from $142.00 to $146.00 and gave the company an "overweight" rating in a report on Thursday, October 16th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories has an average rating of "Moderate Buy" and a consensus price target of $147.00.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares of the company's stock, valued at $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.46% of the company's stock.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.